Wells Fargo
TXG icon

Wells Fargo’s 10x Genomics TXG Stock Holding History

Wells Fargo’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.57M Buy
249,644
+109,528
+78% +$2.87M ﹤0.01% 2223
2026
Q1 		$2.97M Sell
140,116
-204,834
-59% -$4.09M ﹤0.01% 2979
2025
Q4 		$5.63M Buy
344,950
+102,791
+42% +$1.55M ﹤0.01% 2561
2025
Q3 		$2.83M Buy
242,159
+177,485
+274% +$2.31M ﹤0.01% 3066
2025
Q2 		$749K Buy
64,674
+63,535
+5,578% +$579K ﹤0.01% 3877
2025
Q1 		$9.94K Sell
1,139
-254
-18% -$3.2K ﹤0.01% 5882
2024
Q4 		$20K Sell
1,393
-10,535
-88% -$166K ﹤0.01% 5769
2024
Q3 		$269K Buy
11,928
+2,196
+23% +$45.4K ﹤0.01% 4383
2024
Q2 		$189K Sell
9,732
-7,423
-43% -$194K ﹤0.01% 4549
2024
Q1 		$644K Sell
17,155
-9,512
-36% -$418K ﹤0.01% 3725
2023
Q4 		$1.49M Sell
26,667
-11,989
-31% -$522K ﹤0.01% 3133
2023
Q3 		$1.59M Sell
38,656
-6,429
-14% -$334K ﹤0.01% 2969
2023
Q2 		$2.52M Buy
45,085
+7,418
+20% +$401K ﹤0.01% 2717
2023
Q1 		$2.1M Sell
37,667
-33,414
-47% -$1.56M ﹤0.01% 2816
2022
Q4 		$2.59M Sell
71,081
-18,571
-21% -$607K ﹤0.01% 2576
2022
Q3 		$2.55M Sell
89,652
-39,390
-31% -$1.5M ﹤0.01% 2535
2022
Q2 		$5.84M Sell
129,042
-118,646
-48% -$6.16M ﹤0.01% 1972
2022
Q1 		$18.8M Buy
247,688
+54,217
+28% +$4.74M ﹤0.01% 1349
2021
Q4 		$28.8M Sell
193,471
-598,229
-76% -$91.6M 0.01% 1089
2021
Q3 		$115M Buy
791,700
+23,753
+3% +$4.08M 0.03% 591
2021
Q2 		$150M Buy
767,947
+8,574
+1% +$1.55M 0.03% 487
2021
Q1 		$137M Buy
759,373
+706,619
+1,339% +$122M 0.03% 519
2020
Q4 		$7.47M Buy
52,754
+19,293
+58% +$2.8M ﹤0.01% 2357
2020
Q3 		$4.17M Sell
33,461
-230,034
-87% -$24.1M ﹤0.01% 2677
2020
Q2 		$23.5M Sell
263,495
-511,359
-66% -$39.8M 0.01% 1260
2020
Q1 		$48.3M Sell
774,854
-152,908
-16% -$11.9M 0.02% 776
2019
Q4 		$70.7M Buy
927,762
+12,324
+1% +$741K 0.02% 750
2019
Q3 		$46.1M Buy
+915,438
New +$50.7M 0.01% 956

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo's TXG Position: Q2 2026 in Review

Wells Fargo increased its 10x Genomics (TXG) stake by 78% in Q2 2026, buying an estimated $2.87M and bringing the position to 249,644 shares worth $9.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

Wells Fargo first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $150M in Q2 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Wells Fargo held 249,644 shares of 10x Genomics worth $9.57M as of Q2 2026.
  • Wells Fargo bought 109,528 10x Genomics shares in Q2 2026, an estimated $2.87M.
  • 10x Genomics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2223 holding.
  • Wells Fargo first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • Wells Fargo's 10x Genomics position peaked at $150M in Q2 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.